Charles River Laboratories International (NYSE: CRL ) reported earnings on Aug. 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Charles River Laboratories International met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share was unchanged.
Margins contracted across the board.
Charles River Laboratories International notched revenue of $284.7 million. The 11 analysts polled by S&P Capital IQ predicted a top line of $285.4 million on the same basis. GAAP reported sales were 1.2% lower than the prior-year quarter's $288.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.75. The 17 earnings estimates compiled by S&P Capital IQ forecast $0.66 per share. GAAP EPS of $0.63 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 36.4%, 50 basis points worse than the prior-year quarter. Operating margin was 17.3%, 120 basis points worse than the prior-year quarter. Net margin was 10.7%, 50 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $283.0 million. On the bottom line, the average EPS estimate is $0.65.
Next year's average estimate for revenue is $1.15 billion. The average EPS estimate is $2.68.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $38.83.
- Add Charles River Laboratories International to My Watchlist.